Classification updates and clinical investigations in indolent non-Hodgkin lymphoma.
Cheson
Bruce D
BD
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000069461:Bendamustine Hydrochloride; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D006801:Humans; D008224:Lymphoma, Follicular / Q000145:classification* / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D008228:Lymphoma, Non-Hodgkin / Q000145:classification* / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011719:Pyrazines / Q000627:therapeutic use; D000069283:Rituximab; D014750:Vincristine / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D001897:Boronic Acids; D009588:Nitrogen Mustard Compounds; D011719:Pyrazines; C448700:epratuzumab; D000069283:Rituximab; D014750:Vincristine; D000069286:Bortezomib; D003520:Cyclophosphamide; D000069461:Bendamustine Hydrochloride; C437823:galiximab; D011241:Prednisone